Gastrointestinal Cancers | Oncology Today with Dr Neil Love: Role of HER2-Directed Therapy in the Treatment of HER2-Expressing Gastrointestinal Cancers — Part 2 of a Special 3-Part Edition (Companion Faculty Lecture)

Featuring a slide presentation and related discussion from Dr Kanwal Raghav, including the following topics: Prevalence of HER2 alterations among patients with advanced gastrointestinal tumors beyond gastroesophageal cancer (0:00) Dual HER2 inhibition in the treatment of HER2-amplified colorectal cancer (CRC) (4:56) Efficacy and tolerability of the antibody-drug conjugate trastuzumab deruxtecan (T-DXd) for patients with HER2-expressing metastatic CRC (8:52) Activity and safety of the novel bispecific antibody zanidatamab for previously treated HER2-amplified biliary tract cancer (BTC) (14:11) Key findings with tucatinib/trastuzumab for previously treated HER2-positive BTC (21:56) Antitumor activity observed with T-DXd in patients with BTC with HER2 mutations in the Phase II DESTINY-PanTumor02 trial (23:39) CME information and select publications